News
ENZ
1.150
+0.88%
0.010
Enzo Biochem Enhances CFO Patricia Eckert’s Compensation Package
TipRanks · 1d ago
Weekly Report: what happened at ENZ last week (0715-0719)?
Weekly Report · 4d ago
Enzo Biochem: Is This Time Finally Different?
Enzo Biochem's stock is trading near historic lows. Stock has potential for attractive returns with simplified Life Sciences division and strong CEO incentives. Company has $35m in cash after sale of Clinical Labs business to Labcorp Holdings. New CEO has been granted calls with a strike at $2 a share. Valuation potential of $2.00-3.22/share with $75-120m business value.
Seeking Alpha · 07/17 04:49
Weekly Report: what happened at ENZ last week (0708-0712)?
Weekly Report · 07/15 09:25
Weekly Report: what happened at ENZ last week (0701-0705)?
Weekly Report · 07/08 09:26
Weekly Report: what happened at ENZ last week (0624-0628)?
Weekly Report · 07/01 09:26
Weekly Report: what happened at ENZ last week (0617-0621)?
Weekly Report · 06/24 09:27
Enzo Biochem Third Quarter 2024 Earnings: US$0.042 loss per share (vs US$0.16 loss in 3Q 2023)
Enzo Biochem shares are down 9.2% from a week ago. The company reported a loss of US$2.13m in the third quarter of 2024. The stock is down 10% from its highs in the last week. There are 3 warning signs for Enzo biochem.
Simply Wall St · 06/19 10:58
Weekly Report: what happened at ENZ last week (0610-0614)?
Weekly Report · 06/17 09:25
Enzo Biochem (ENZ) Q3 Earnings Improve Y/Y, Gross Margin Up
NASDAQ · 06/14 17:18
ENZ Stock Earnings: Enzo Biochem Reported Results for Q3 2024
Enzo Biochem just reported results for the third quarter of 2024. The company reported earnings per share of -4 cents and revenue of $8.02 million. InvestorPlace Earnings is a project that automates coverage of quarterly earnings reports to help readers understand the figures.
Investorplace · 06/14 01:52
Enzo Biochem Non-GAAP EPS of -$0.03, revenue of $8.02M
Seeking Alpha · 06/13 20:52
Press Release: Enzo Biochem Reports Third Quarter Fiscal 2024 Results and Provides Business Update
Dow Jones · 06/13 20:20
Press Release: Enzo Biochem Reports Third Quarter -2-
Dow Jones · 06/13 20:20
Enzo Biochem: Fiscal Q3 Earnings Snapshot
Enzo Biochem Inc. Reported a loss of $3 million in its fiscal third quarter. The life sciences and biotechnology company posted revenue of $8 million in the period. On a per-share basis, the Farmingdale, New York-based company lost 6 cents.
Barchart · 06/13 15:32
Weekly Report: what happened at ENZ last week (0603-0607)?
Weekly Report · 06/10 09:26
Earnings week ahead: Oracle, Adobe, Broadcom and more
Earnings week ahead: Oracle, Adobe, Broadcom and more are scheduled to release their quarterly updates. Fuelcell Energy, Adobe and Signet Jewelers are among the notable companies scheduled to report their results next week. The week of June 10 to 14 also includes quarterly updates from Oracle, Signet and more.
Seeking Alpha · 06/09 12:01
Weekly Report: what happened at ENZ last week (0527-0531)?
Weekly Report · 06/03 09:27
Weekly Report: what happened at ENZ last week (0520-0524)?
Weekly Report · 05/27 09:27
Weekly Report: what happened at ENZ last week (0513-0517)?
Weekly Report · 05/20 09:26
More
Webull provides a variety of real-time ENZ stock news. You can receive the latest news about Enzo Biochem Inc through multiple platforms. This information may help you make smarter investment decisions.
About ENZ
Enzo Biochem, Inc. is focused on molecular diagnostics and has a portfolio of technical platforms and reagent sets supporting a diverse range of biomedical research and translational science needs. The Company operates through the product segment, which manufactures, develops and markets products and tools for clinical research, translational research, drug development and bioscience research customers worldwide. The Company is engaged in product development and manufactures and supplies a comprehensive portfolio of products, including antibodies, genomic probes, assays, biochemicals and proteins. The Company's products and technologies are used in translational research and drug development areas, including cell biology, genomics, assays, immunohistochemistry and small molecule chemistry. Its life science division supports the work of research centers and industry partners. It has built a portfolio of intellectual property assets, comprised of around 457 owned patents worldwide.